Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA; Tauriel Investigators. Teng E, et al. Among authors: manser pt. JAMA Neurol. 2022 Aug 1;79(8):758-767. doi: 10.1001/jamaneurol.2022.1375. JAMA Neurol. 2022. PMID: 35696185 Free PMC article. Clinical Trial.
[18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer's disease.
Sanabria Bohórquez S, Marik J, Ogasawara A, Tinianow JN, Gill HS, Barret O, Tamagnan G, Alagille D, Ayalon G, Manser P, Bengtsson T, Ward M, Williams SP, Kerchner GA, Seibyl JP, Marek K, Weimer RM. Sanabria Bohórquez S, et al. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2077-2089. doi: 10.1007/s00259-019-04399-0. Epub 2019 Jun 28. Eur J Nucl Med Mol Imaging. 2019. PMID: 31254035
Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology.
Blennow K, Chen C, Cicognola C, Wildsmith KR, Manser PT, Bohorquez SMS, Zhang Z, Xie B, Peng J, Hansson O, Kvartsberg H, Portelius E, Zetterberg H, Lashley T, Brinkmalm G, Kerchner GA, Weimer RM, Ye K, Höglund K. Blennow K, et al. Among authors: manser pt. Brain. 2020 Feb 1;143(2):650-660. doi: 10.1093/brain/awz346. Brain. 2020. PMID: 31834365 Free PMC article.
Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.
Ayalon G, Lee SH, Adolfsson O, Foo-Atkins C, Atwal JK, Blendstrup M, Booler H, Bravo J, Brendza R, Brunstein F, Chan R, Chandra P, Couch JA, Datwani A, Demeule B, DiCara D, Erickson R, Ernst JA, Foreman O, He D, Hötzel I, Keeley M, Kwok MCM, Lafrance-Vanasse J, Lin H, Lu Y, Luk W, Manser P, Muhs A, Ngu H, Pfeifer A, Pihlgren M, Rao GK, Scearce-Levie K, Schauer SP, Smith WB, Solanoy H, Teng E, Wildsmith KR, Bumbaca Yadav D, Ying Y, Fuji RN, Kerchner GA. Ayalon G, et al. Sci Transl Med. 2021 May 12;13(593):eabb2639. doi: 10.1126/scitranslmed.abb2639. Sci Transl Med. 2021. PMID: 33980574 Clinical Trial.
The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
Teng E, Manser PT, Shah M, Pickthorn K, Hu N, Djakovic S, Swendsen H, Blendstrup M, Faccin G, Ostrowitzki S, Sink KM. Teng E, et al. Among authors: manser pt. J Prev Alzheimers Dis. 2023;10(1):41-49. doi: 10.14283/jpad.2022.101. J Prev Alzheimers Dis. 2023. PMID: 36641609
Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.
Jamalian S, Dolton M, Chanu P, Ramakrishnan V, Franco Y, Wildsmith K, Manser P, Teng E, Jin JY, Quartino A, Hsu JC; Alzheimer's Disease Neuroimaging Initiative. Jamalian S, et al. CPT Pharmacometrics Syst Pharmacol. 2023 Jul;12(7):1029-1042. doi: 10.1002/psp4.12974. Epub 2023 May 2. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37101394 Free PMC article.
15 results